Clinical Trial Update: Topotecan Using Convection-Enhanced Delivery (CED) in High Grade Glioma [EARLY_Phase 1]

View source ↗

Summary

An early Phase 1 trial of topotecan delivered via convection-enhanced delivery for high-grade glioma (WHO Grade III or IV) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Glioblastoma

Drugs mentioned

• Topotecan (topotecan)

Snippet

Sponsor: Michael Vogelbaum, MD, PhD | Conditions: Malignant Glioma, WHO Grade III or IV Recurrent Glioma | EARLY_Phase 1 | Status: COMPLETED